Brief: Palatin Technologies Announces Positive Results From Phase 2 Study Of Pl9643 In Patients With Dry Eye Disease

Palatin Technologies

15/12/2020 13:39

Dec 15 (Reuters) - Palatin Technologies Inc  PTN.A :
    * PALATIN TECHNOLOGIES ANNOUNCES POSITIVE RESULTS FROM ITS
PHASE 2
STUDY OF PL9643 IN PATIENTS WITH DRY EYE DISEASE
    * PALATIN TECHNOLOGIES INC - PHASE 2/3 CLINICAL TRIAL
CURRENTLY
PLANNED FOR MID-2021
    * PALATIN TECHNOLOGIES INC - THERE WERE NO SAFETY SIGNALS
IDENTIFIED AND PL9643 HAD EXCELLENT OCULAR TOLERABILITY IN TRIAL
    * PALATIN TECHNOLOGIES INC - STATISTICALLY SIGNIFICANT
IMPROVEMENT
IN MODERATE-TO-SEVERE PATIENTS FOR MULTIPLE SIGN AND SYMPTOM
MEASURES IN STUDY
    * PALATIN TECHNOLOGIES INC - STATISTICAL SIGNIFICANCE FOR
PRIMARY
ENDPOINTS WAS NOT REACHED IN OVERALL ENROLLED POPULATION IN
STUDY

Source text for Eikon:  ID:nPn9lwf4Ca 
Further company coverage:  PTN.A 

 ((Reuters.Briefs@thomsonreuters.com;))